<DOC>
	<DOCNO>NCT02311088</DOCNO>
	<brief_summary>Ticagrelor treatment associate increased rate dyspnea , previous study imply possible role adenosine . The purpose study determine caffeine-antagonist effective reduce dyspnea relate ticagrelor .</brief_summary>
	<brief_title>Trial Caffeine Alleviate Dyspnea Related Ticagrelor</brief_title>
	<detailed_description />
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<criteria>Age â‰¥ 18 year Recent acute coronary syndrome ongoing ticagrelor treatment Stabilized clinical condition plan additional revascularization Dyspnea onset start ticagrelor treatment Willingness abstain caffeine intake ( e.g . coffee , tea , colatype beverage ; food , nutritional supplement medication contain caffeine ) duration study Provision sign informed consent form Chronic obstructive pulmonary disease , asthma know pulmonary disease require daily medical therapy Obstructive sleep apnea syndrome require therapy Ongoing sign symptom heart failure* , evidence moderately severely reduced leave ventricular ( LV ) function Renal failure , glomerular filtration rate ( GFR ) &lt; 30 dialysis Pregnancy lactation Known allergy ticagrelor , caffeine , know intolerance caffeine Ongoing treatment follow : quinolone antibiotic , fluvoxamine , phenylpropanolamine , carbamazepine , clozapine , lithium , nonsteroidal antiinflammatory drug ( NSAIDs ) ; drug contain theophylline caffeine . Any condition seriously increase risk noncompliance loss followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>